Check out the ACC.19 Meeting Coverage Page for post-meeting content to reinforce the teaching points and education presented during ACC.19. In a recent Expert Analysis, Michael D. Miedema, MD, and Thomas Knickelbine, MD, FACC, discuss if it is time to end our relationship with aspirin for primary prevention of cardiovascular disease. They explain how it is important to first understand the details of three new trials studying aspirin and how they fit in the context of prior aspirin research. View additional learning pathway presentations in iScience, the ACC.19 Meeting on Demand™ Program. Stay tuned as more content will be added to the ACC.19 Meeting Coverage Page, and check out ACC's Primary Prevention of Cardiovascular Disease Guideline Hub.